REG - Yourgene Health PLC - Issue of Share Options

Yourgene HealthAnnouncement

19/06/2020 16:45

RNS Number : 5578Q
  
Yourgene Health PLC
  
19 June 2020
  
 

 
Yourgene Health plc
("Yourgene" or the "Company")
 
Issue of Share Options
 
Manchester, UK - 19 June 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the issuance of 470,000 share options under its existing share option scheme to two employees.
 
The new share options have performance conditions based on EPS growth over the next three years, in line with the Company's share option scheme rules and previously issued share options. The exercise price of these options is 18 pence.  The total number of share options now in issue is 61,379,232, representing 9.8% of the as-enlarged share capital.
 
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
 



Yourgene Health plc
Lyn Rees, Chief Executive Officer


Tel: +44 (0)161 669 8122
investors@yourgene-health.com 




Barry Hextall, Chief Financial Officer








Joanne Cross, Director of Marketing


















Cairn Financial Advisers LLP (NOMAD)


Tel: +44 (0)20 7213 0880




Liam Murray / James Caithie / Ludovico Lazzaretti


















Stifel Nicolaus Europe Limited (Sole Corporate Broker)


Tel: +44 (0)20 7710 7600




Nicholas Moore / Matthew Blawat / Ben Maddison


















Walbrook PR Ltd (Media and Investor Relations)
 


Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
 




Paul McManus / Lianne Cawthorne 


Mob: 07980 541 893 / Mob: 07584 391 303  








 
 
About Yourgene Health plc
Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.  
 
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
 
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.
 
Yourgene is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
IOEUKOVRRKUNAAR